Nizal S. Chandrakumar

Array ( [id] => 16806032 [patent_doc_number] => 20210128585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 17/105300 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17105300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16869997 [patent_doc_number] => 20210163464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => PYRIDINE COMPOUND [patent_app_type] => utility [patent_app_number] => 17/103515 [patent_app_country] => US [patent_app_date] => 2020-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17103515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18107942 [patent_doc_number] => 20230000822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => A COMBINATION OF A BTK INHIBITOR AND ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS [patent_app_type] => utility [patent_app_number] => 17/779328 [patent_app_country] => US [patent_app_date] => 2020-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17014097 [patent_doc_number] => 11083716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof [patent_app_type] => utility [patent_app_number] => 17/101686 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 31367 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091239 [patent_doc_number] => 20220409580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/777963 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091290 [patent_doc_number] => 20220409631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE [patent_app_type] => utility [patent_app_number] => 17/776922 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18301085 [patent_doc_number] => 11622971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Tryptamine compositions for enhancing neurite outgrowth [patent_app_type] => utility [patent_app_number] => 16/951009 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 28921 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18301085 [patent_doc_number] => 11622971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Tryptamine compositions for enhancing neurite outgrowth [patent_app_type] => utility [patent_app_number] => 16/951009 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 28921 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18301085 [patent_doc_number] => 11622971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Tryptamine compositions for enhancing neurite outgrowth [patent_app_type] => utility [patent_app_number] => 16/951009 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 28921 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18301085 [patent_doc_number] => 11622971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Tryptamine compositions for enhancing neurite outgrowth [patent_app_type] => utility [patent_app_number] => 16/951009 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 28921 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17634980 [patent_doc_number] => 11345692 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-31 [patent_title] => 3-vinylquinolines as cancer cells inhibitors [patent_app_type] => utility [patent_app_number] => 17/098744 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 21 [patent_no_of_words] => 15496 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806025 [patent_doc_number] => 20210128578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE [patent_app_type] => utility [patent_app_number] => 17/098678 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 278 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982514 [patent_doc_number] => 20220348550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => 2-(1,2,4-TRIAZOLYL) BENZOYL ARYLAMINE ACTIVE COMPOUND FOR INHIBITING WHEAT TAKE-ALL PATHOGEN [patent_app_type] => utility [patent_app_number] => 17/629254 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609734 [patent_doc_number] => 20220152013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => SOLID ORAL NICOTINE FORMULATION [patent_app_type] => utility [patent_app_number] => 17/098550 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19324860 [patent_doc_number] => 12042513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof [patent_app_type] => utility [patent_app_number] => 17/093832 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 20 [patent_no_of_words] => 47531 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 575 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17093832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140090 [patent_doc_number] => 20210308101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => METHODS OF TREATING FIBROMYALGIA [patent_app_type] => utility [patent_app_number] => 17/094595 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822614 [patent_doc_number] => 20210137907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/091019 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656048 [patent_doc_number] => 20210052684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOOD [patent_app_type] => utility [patent_app_number] => 17/091128 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692459 [patent_doc_number] => 20230322703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/766435 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647753 [patent_doc_number] => 20230293524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY [patent_app_type] => utility [patent_app_number] => 17/772727 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772727 [rel_patent_id] =>[rel_patent_doc_number] =>)